Get started
Author

Alcibiade Athanasiou

Observed names: A. Athanasiou, Athanasiou, Alcibiade
ORCID: 0000-0002-8145-8325
Observed ORCID: 0000-0002-8145-8325
OpenAlex ID: A5055929405
Structure-guided design, synthesis and biological evaluation of novel DNA ligase inhibitors with in vitro and in vivo anti-staphylococcal activity
2012 · Jean-Philippe Surivet, Roland Lange, et al. · Bioorganic & Medicinal Chemistry Letters · 36
Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies
2018 · Thomas Steuber, Pierre Tennstedt, et al. · British Journal of Urology · 32
PDF
Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer
2020 · Annalisa Macagno, Alcibiade Athanasiou, et al. · PLoS ONE · 24
PDF
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index
2022 · Daniela Terracciano, Evelina La Civita, et al. · The Prostate · 22
Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics Technology
2024 · Alcibiade Athanasiou, Natasha Kureshi, et al. · Journal of Proteome Research · 20
PDF
Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer
2017 · Kathrin Endt, Jens Goepfert, et al. · PLoS ONE · 17
PDF
A High Performing Biomarker Signature for Detecting Early-Stage Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
2025 · Norma A. Palma, Aimee L. Lucas, et al. · Cancers · 13
PDF
Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging
2023 · Juan Morote, Hayley Pye, et al. · British Journal of Urology · 13
PDF
Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer
2022 · Sandra Goetze, Peter Schüffler, et al. · Clinical Proteomics · 9
PDF
A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology
2021 · Alcibiade Athanasiou, Pierre Tennstedt, et al. · PLoS ONE · 7
PDF
Evaluation of Proclarix in the diagnostic work‐up of prostate cancer
2023 · Basil Kaufmann, Sharon Fischer, et al. · BJUI Compass · 3
PDF
Thrombospondin 1 and cathepsin D improve the detection of high-grade prostate cancer and reduce the number of unnecessary prostate biopsies
2018 · H. Klocker, E. Steiner, et al. · European Urology Supplements · 1
Proclarix’ performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population
2026 · Ralph Schiess, Alcibiade Athanasiou, et al. · BMC Cancer
The Prognostic Value of Proclarix in Prostate Cancer Patients Under Active Surveillance: Predicting Transition to Active Treatment and Disease Progression in a Danish Cohort
2026 · Alcibiade Athanasiou, Torben F. Hansen, et al. · Cancers
PDF
Abstract B027: A blood-based, multiplex protein biomarker signature shows superior performance in detection of early-stage pancreatic ductal adenocarcinoma (PDAC)
2024 · Norma Palma, Ralph Schiess, et al. · Cancer Research
Development of a multi-analyte blood test for the early detection of pancreatic ductal adenocarcinoma (PDAC) and performance compared to CA19-9.
2024 · Alcibiade Athanasiou, Natasha Kureshi, et al. · Journal of Clinical Oncology
Additional file 1 of Use of MS-GUIDE for identification of protein biomarkers for risk stratification of patients with prostate cancer
2022 · Goetze, Sandra, Schüffler, Peter, et al. · Figshare
Works count: 21
Citation count: 197
H-index: 9
I10-index: 8
Year
Topic
Type